Page 27 - Tim Walbert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Horizon Therapeutics to Expand Pipeline, R&D with $3B Viela Bio Acquisition Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyer's pipeline and R&D. [Viela Bio] February 1, 2021 Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said, in a deal designed to strengthen the buyer's pipeline and R&D. [Viela Bio] Share Horizon Therapeutics has agreed to acquire Viela Bio for approximately $3.05 billion, the companies said today—less than three weeks af...

Horizon Therapeutics plc (NASDAQ: HZNP) and Viela Bio, Inc. (NASDAQ: VIE) have entered into a definitive agreement where Horizon will acquire all issues and outstanding shares of Vielo Bio common stock for USD 53 per share in cash or a fully diluted equity value of USD 3.05 Billion.  The transaction is expected to close by the end of the first quarter of 2021.  “This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term,” said Tim Walbert, chairman, president and chief executive offic...

Source: Streetwise Reports  (2/1/21) Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. Prior to the opening of U.S. market for trading today, clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ), which is focused on pioneering treatments for autoimmune and severe inflammatory diseases and Horizon Therapeutics Plc (HZNP:NASDAQ), announced that the companies have "entered into a definitive agreement under which Horizon will acquire all of the i...

Horizon Therapeutics plc Announces Short-Term TEPEZZA (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production IMPORTANT SAFETY INFORMATION Warnings and Precautions Infusion Reactions: TEPEZZA may cause infusion reactions. Infusion reactions have been reported in approximately 4% of patients treated with TEPEZZA. Reported infusion reactions have usually been mild or moderate in severity. Signs and symptoms may include transient increases in blood pressure, feeling hot, tachycardia, dyspnea, headache and muscular pain. Infusion reactio...